CoChat
Sign Up
Cited by 132Pharmaceutical studies and practicesPharmaceutical industry and healthcarePharmacy and Medical Practices

Pediatric Information in Drug Product Labeling

Avant, Debbie·2012·JAMA
DOI 10.1001/jama.2012.3435
Open this paper in CoChat — free account

Abstract

To the Editor: The dearth of information on drugs for children led to children being called "therapeutic orphans."In 1975, Wilson determined that 78% of drug labeling had inadequate pediatric information. 1In 1999, Wilson summarized 25 years of efforts to get pediatric information into labeling and extended his analysis. 2In the decade after Wilson's review, regulations and legislation have led to more pediatric studies and labeling. 3We hypothesized that a higher percentage of labeling has information on use in children compared with the analyses by Wilson in 1975 1 and in 1999. 2Methods.We evaluated labeling in the June 2009 electronic Physicians' Desk Reference 4 (ePDR) using methods established by Wilson 1 in analyzing the 1973 print PDR.Labeling was categorized as adequate if it stated that the drug was approved for pediatric use, had been studied, or had safety, efficacy, or dosing information for all appropriate pediatric populations; and inadequate if labeling lacked data on dosing, safety, or efficacy in at least 1 pediatric subpopulation.Partially labeled was a subgroup of inadequately labeled and defined as adequate labeling for at least 1 but not all appropriate pediatric subpopulations.Labeling in the ePDR was reviewed by 3 people (A.N.S., D.A., W.R.).Differences were reviewed by a fourth person who made final assignments (M.D.M.).The was 0.91.Topicals, nasal sprays and most over-the-counter products were excluded per the methods of Wilson.In products with multiple formulations, only 1 likely to be used in children (ie, oral formulation) was analyzed.Because limitations in the ePDR may lead to an underestimate of pediatric labeling, 2 subanalyses were performed.First we excluded products on the US Food and Drug Administration's (FDA's) list of Products Deemed Not Relevant to Pediatrics. 5 Second, we compared the ePDR list with the FDA's Pediatric Labeling Changes Table (February 1998-June 2009), which reflects only pediatric legislative initiatives and is not comprehensive, to determine whether most new pediatric labeling changes were included in the ePDR. 3 Similar to Wilson, 2 we also assessed the labeling for all new molecular entities (NMEs) approved between 2002 and 2008 6 to determine if the product might be used in pediatrics and the adequacy of the pediatric information.

Integrity signals

Registry

Crossref · 10.1001/jama.2012.3435

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Related

Authors
Avant, D.
Affiliations
University of Maryland, Baltimore (US)
Corresponding author
Avant, Debbie
Venue
JAMA
Publisher
American Medical Association (AMA)
Published
2012-05-09
Volume
307
Issue
18
Pages
1914
ISSN
  • 0002-9955 (ISSN-L)
  • 0098-7484
DOI
10.1001/jama.2012.3435
OpenAlex
W2084510697
Cited by
132
References
1
Citations by year
2026: 1 · 2025: 6 · 2024: 8 · 2023: 10 · 2022: 10 · 2021: 8 · 2020: 13 · 2019: 15 · 2018: 12 · 2017: 11 · 2016: 5 · 2015: 6 · 2014: 14 · 2013: 10 · 2012: 1
FWCI
8.69
Type
journal article
Language
en
Open access
closed
Locations
  • JAMA (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmaceutical industry and healthcare
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacy and Medical Practices
Keywords
pediatric drug labeling, drug labeling, Physicians' Desk Reference, new chemical entities, pediatric drug development, therapeutic orphans
MeSH terms
Contraindications, Age Factors, Child, Drug Labeling, Pharmaceutical Preparations, Humans, Reference Books, United States, United States Food and Drug Administration, Drug Approval, Drug-Related Side Effects and Adverse Reactions

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review